Get the Stockscreener App
2.39
1.65%
-0.04
After Hours:
2.35
-0.04
-1.67%
Inmed Pharmaceuticals Inc stock is traded at $2.39, with a volume of 50,579.
It is down -1.65% in the last 24 hours and down -22.65% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
See More
Previous Close:
$2.43
Open:
$2.41
24h Volume:
50,579
Relative Volume:
0.02
Market Cap:
$4.79M
Revenue:
$4.96M
Net Income/Loss:
$-6.82M
P/E Ratio:
-0.0365
EPS:
-65.4
Net Cash Flow:
$-6.64M
1W Performance:
-9.47%
1M Performance:
-22.65%
6M Performance:
-22.40%
1Y Performance:
-33.20%
1-Day Range:
$2.3101
$2.41
1-Week Range:
$2.3101
$2.71
52-Week Range:
$1.72
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
2.39 | 4.87M | 4.96M | -6.82M | -6.64M | -65.40 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
What institutional investors are buying InMed Pharmaceuticals Inc. stockBuild wealth faster with professional insights - jammulinksnews.com
Does InMed Pharmaceuticals Inc. stock perform well during market downturnsHigh-octane gains - jammulinksnews.com
What are analysts’ price targets for InMed Pharmaceuticals Inc. in the next 12 monthsMaximize gains with professional stock picks - jammulinksnews.com
Is it the right time to buy InMed Pharmaceuticals Inc. stockMaximize portfolio value with smart investment plans - jammulinksnews.com
What analysts say about InMed Pharmaceuticals Inc. stockFree Trading Strategy Suggestions - jammulinksnews.com
How volatile is InMed Pharmaceuticals Inc. stock compared to the marketCapitalize on momentum-driven investment opportunities - jammulinksnews.com
What are InMed Pharmaceuticals Inc. company’s key revenue driversMaximize portfolio growth with professional advice - jammulinksnews.com
What is the risk reward ratio of investing in InMed Pharmaceuticals Inc. stockUnstoppable profit momentum - jammulinksnews.com
Will InMed Pharmaceuticals Inc. outperform the marketEquity Market Return Forecast Model Update - Newser
What makes InMed Pharmaceuticals Inc. stock price move sharplyAdvanced Screener Entry Points For Consistent Profits - jammulinksnews.com
News impact scoring models applied to InMed Pharmaceuticals IncShort Term Gain Strategy with AI Logic - Newser
What moving averages say about InMed Pharmaceuticals Inc.Free Early Entry Tips With Low Risk Zone - Newser
News impact scoring models applied to InMed Pharmaceuticals Inc.Alpha Stock Picks with Chart Confirmation - Newser
How InMed Pharmaceuticals Inc. stock performs during market volatilityAI Screener Based Stock Summary Report - Newser
Why InMed Pharmaceuticals Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser
Exit strategy if you’re trapped in InMed Pharmaceuticals Inc.Real-Time Setup Summary with ROI Focus - Newser
Why InMed Pharmaceuticals Inc. stock is on top investor watchlistsWeekly Entry Signal Based Forecast Tool - Newser
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules – IT Business Net - IT Business Net
INM files 8-K on upcoming INM-901 Alzheimer’s data at AAIC 2025 | INM SEC FilingForm 8-K - Stock Titan
Published on: 2025-07-28 16:29:31 - beatles.ru
Price Channel Expanding on InMed Pharmaceuticals Inc.’s ChartSecure Capital Picks With Upside Potential Tracked - metal.it
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - TradingView
Promising Alzheimer's Drug INM-901 Demonstrates Breakthrough Results in Advanced Disease Treatment - Stock Titan
Published on: 2025-07-28 04:56:47 - Newser
Published on: 2025-07-28 03:47:35 - Newser
What are the technical indicators suggesting about InMed Pharmaceuticals Inc.Superior capital gains - jammulinksnews.com
Published on: 2025-07-28 05:33:11 - jammulinksnews.com
How strong is InMed Pharmaceuticals Inc. company’s balance sheetUnlock real-time stock alerts for quick profits - jammulinksnews.com
Is InMed Pharmaceuticals Inc. stock overvalued or undervaluedAchieve rapid portfolio appreciation today - jammulinksnews.com
What are the latest earnings results for InMed Pharmaceuticals Inc.Discover stocks with superior performance - jammulinksnews.com
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):